Inhaled corticosteroids plus standard care vs placebo or usual care: Adverse events
Inhaled corticosteroids plus standard care showed no clear difference in adverse events compared with standard care (with or without placebo) (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Inhaled corticosteroids plus standard care vs standard care (with or without placebo) Adverse events · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1… Inhaled corticosteroids plus standard care showed no clear difference in adverse events compared with standard care (with or without placebo) (low certainty). Inhaled corticosteroids for the treatment of COVID‐19 (2022) · Cochrane Headline outcomes only | RR 0.78 [0.47, 1.31] | 1 study · 400 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Inhaled corticosteroids for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.